$RKDA
Arcadia Biosciences, Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023022199 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $1.389M $1.509M
YoY Change -64.0% -53.14%
Cost Of Revenue $981.0K $825.0K
YoY Change -71.54% -76.14%
Gross Profit $408.0K $684.0K
YoY Change -0.73% -387.39%
Gross Profit Margin 29.37% 45.33%
Selling, General & Admin $3.815M $4.392M
YoY Change -17.99% 0.99%
% of Gross Profit 935.05% 642.11%
Research & Development $391.0K $359.0K
YoY Change 8.91% -9.11%
% of Gross Profit 95.83% 52.49%
Depreciation & Amortization $67.00K $71.00K
YoY Change -52.48% -52.35%
% of Gross Profit 16.42% 10.38%
Operating Expenses $4.206M $4.751M
YoY Change -16.06% 0.15%
Operating Profit -$3.791M -$4.048M
YoY Change 0.21% -12.44%
Interest Expense $4.623M $1.138M
YoY Change 15310.0% 113700.0%
% of Operating Profit
Other Income/Expense, Net -$13.00K $32.00K
YoY Change -70.45% 128.57%
Pretax Income $819.0K -$9.384M
YoY Change -121.57% 103.56%
Income Tax $1.000K
% Of Pretax Income 0.12%
Net Earnings $823.0K -$9.384M
YoY Change -121.79% 109.09%
Net Earnings / Revenue 59.25% -621.87%
Basic Earnings Per Share $0.61 -$10.86
Diluted Earnings Per Share $0.61 -$10.86
COMMON SHARES
Basic Shares Outstanding 950.4K 857.6K
Diluted Shares Outstanding 1.358M 864.4K

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.51M $23.00M
YoY Change -12.84% -6.33%
Cash & Equivalents $13.50M $23.00M
Short-Term Investments $5.023M
Other Short-Term Assets $1.038M $693.0K
YoY Change -38.76% -26.67%
Inventory $3.164M $2.591M
Prepaid Expenses
Receivables $630.0K $923.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $23.34M $27.21M
YoY Change -22.35% -13.63%
LONG-TERM ASSETS
Property, Plant & Equipment $560.0K $622.0K
YoY Change -41.3% -57.63%
Goodwill
YoY Change
Intangibles $40.00K $40.00K
YoY Change -89.64% -91.51%
Long-Term Investments
YoY Change
Other Assets $178.0K $165.0K
YoY Change 7.23% 3.77%
Total Long-Term Assets $3.459M $3.205M
YoY Change -30.12% -56.1%
TOTAL ASSETS
Total Short-Term Assets $23.34M $27.21M
Total Long-Term Assets $3.459M $3.205M
Total Assets $26.80M $30.41M
YoY Change -23.45% -21.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.816M $2.800M
YoY Change 3292.77% 3957.97%
Accrued Expenses $993.0K $1.014M
YoY Change -0.1% -2.12%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change
Total Short-Term Liabilities $4.091M $4.097M
YoY Change -13.69% -14.81%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.000M $2.000M
YoY Change 0.0% -1.91%
Total Long-Term Liabilities $2.000M $2.000M
YoY Change 0.0% -1.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.091M $4.097M
Total Long-Term Liabilities $2.000M $2.000M
Total Liabilities $9.068M $13.72M
YoY Change 10.05% 60.31%
SHAREHOLDERS EQUITY
Retained Earnings -$266.4M -$267.2M
YoY Change 6.26% 8.18%
Common Stock $284.3M $284.1M
YoY Change 2.42% 2.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $17.87M $16.83M
YoY Change
Total Liabilities & Shareholders Equity $26.80M $30.41M
YoY Change -23.45% -21.62%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income $823.0K -$9.384M
YoY Change -121.79% 109.09%
Depreciation, Depletion And Amortization $67.00K $71.00K
YoY Change -52.48% -52.35%
Cash From Operating Activities -$4.798M -$3.500M
YoY Change 42.59% -28.57%
INVESTING ACTIVITIES
Capital Expenditures $5.000K $0.00
YoY Change -183.33% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$4.711M $315.0K
YoY Change -8824.07% -59.97%
Cash From Investing Activities -$4.716M $315.0K
YoY Change -9925.0% -57.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 5.505M
YoY Change 137525.0%
NET CHANGE
Cash From Operating Activities -4.798M -3.500M
Cash From Investing Activities -4.716M 315.0K
Cash From Financing Activities 0.000 5.505M
Net Change In Cash -9.514M 2.354M
YoY Change 186.83% -156.94%
FREE CASH FLOW
Cash From Operating Activities -$4.798M -$3.500M
Capital Expenditures $5.000K $0.00
Free Cash Flow -$4.803M -$3.500M
YoY Change 42.99% -29.15%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001469443
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-37383
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Arcadia Biosciences, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-0571538
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
5950 Sherry Lane
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 215
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Dallas
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
75225
CY2023Q1 dei City Area Code
CityAreaCode
214
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
974-8921
CY2023Q1 dei Security12b Title
Security12bTitle
Common
CY2023Q1 dei Trading Symbol
TradingSymbol
RKDA
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
950406
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22998000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20644000
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
18000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3000
CY2023Q1 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
923000
CY2022Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
1287000
CY2023Q1 us-gaap Inventory Net
InventoryNet
2591000
CY2022Q4 us-gaap Inventory Net
InventoryNet
2571000
CY2023Q1 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
87000
CY2022Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
87000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
606000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
809000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
27205000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
25398000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
622000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
704000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1618000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1848000
CY2023Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
760000
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
767000
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
40000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
40000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
165000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
165000
CY2023Q1 us-gaap Assets
Assets
30410000
CY2022Q4 us-gaap Assets
Assets
28922000
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2785000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2881000
CY2023Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
15000
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
48000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1014000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1010000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
283000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
270000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4097000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4209000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
760000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1007000
CY2023Q1 rkda Common Stock Warrant And Option Liabilities
CommonStockWarrantAndOptionLiabilities
6861000
CY2022Q4 rkda Common Stock Warrant And Option Liabilities
CommonStockWarrantAndOptionLiabilities
806000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2000000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2000000
CY2023Q1 us-gaap Liabilities
Liabilities
13718000
CY2022Q4 us-gaap Liabilities
Liabilities
8022000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
857572
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
857572
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
616079
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
616079
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
65000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
65000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
284003000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
278827000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-267243000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-257859000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
16825000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
21033000
CY2023Q1 us-gaap Minority Interest
MinorityInterest
-133000
CY2022Q4 us-gaap Minority Interest
MinorityInterest
-133000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
16692000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
20900000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30410000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28922000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1509000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3220000
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
825000
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3458000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
359000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
395000
CY2023Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-31000
CY2023Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
19000
CY2022Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
328000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4392000
CY2022Q1 rkda Issuance And Offering Costs Allocated To Liability Classified Options
IssuanceAndOfferingCostsAllocatedToLiabilityClassifiedOptions
0
CY2023Q1 rkda Gain Loss On Private Placement
GainLossOnPrivatePlacement
-6076000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4349000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
5557000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
7843000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4048000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4623000
CY2023Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
198000
CY2022Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
32000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
14000
CY2023Q1 rkda Gain Loss On Private Placement
GainLossOnPrivatePlacement
-6076000
CY2022Q1 rkda Gain Loss On Private Placement
GainLossOnPrivatePlacement
0
CY2023Q1 rkda Change In Fair Value Of Common Stock Warrant And Option Liabilities
ChangeInFairValueOfCommonStockWarrantAndOptionLiabilities
940000
CY2022Q1 rkda Change In Fair Value Of Common Stock Warrant And Option Liabilities
ChangeInFairValueOfCommonStockWarrantAndOptionLiabilities
0
CY2023Q1 rkda Issuance And Offering Costs Allocated To Liability Classified Options
IssuanceAndOfferingCostsAllocatedToLiabilityClassifiedOptions
430000
CY2022Q1 rkda Issuance And Offering Costs Allocated To Liability Classified Options
IssuanceAndOfferingCostsAllocatedToLiabilityClassifiedOptions
0
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-9384000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-4610000
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-122000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9384000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4488000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.86
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.86
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.09
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.09
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
864391
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
864391
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
554675
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
554675
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
20900000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
5000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
212000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-9384000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
16692000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
31196000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
4000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
260000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-4610000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
30242000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-9384000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-4610000
CY2023Q1 rkda Change In Fair Value Of Common Stock Warrant And Option Liabilities
ChangeInFairValueOfCommonStockWarrantAndOptionLiabilities
940000
CY2022Q1 rkda Change In Fair Value Of Common Stock Warrant And Option Liabilities
ChangeInFairValueOfCommonStockWarrantAndOptionLiabilities
0
CY2023Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-0
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-31000
CY2023Q1 rkda Issuance And Offering Costs Allocated To Liability Classified Options
IssuanceAndOfferingCostsAllocatedToLiabilityClassifiedOptions
430000
CY2022Q1 rkda Gain Loss On Private Placement
GainLossOnPrivatePlacement
0
CY2023Q1 us-gaap Depreciation
Depreciation
71000
CY2022Q1 us-gaap Depreciation
Depreciation
149000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
13000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
180000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
166000
CY2023Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
19000
CY2022Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
328000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
212000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
260000
CY2023Q1 us-gaap Inventory Write Down
InventoryWriteDown
23000
CY2022Q1 us-gaap Inventory Write Down
InventoryWriteDown
368000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-80000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1398000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
37000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-669000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-203000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-208000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-22000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-149000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-198000
CY2023Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-33000
CY2022Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
5000
CY2023Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
12000
CY2022Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
0
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-191000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-180000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3466000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4885000
CY2023Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
30000
CY2022Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
787000
CY2023Q1 us-gaap Proceeds From Sale Of Equity Method Investments
ProceedsFromSaleOfEquityMethodInvestments
285000
CY2022Q1 us-gaap Proceeds From Sale Of Equity Method Investments
ProceedsFromSaleOfEquityMethodInvestments
0
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
40000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
315000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
747000
CY2023Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
5000
CY2022Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
4000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5505000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2354000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4134000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20644000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28685000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22998000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24551000
CY2023Q1 rkda Debt And Equity Securities Accumulated Gross Unrealized Gain Before Tax
DebtAndEquitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2023Q1 rkda Debt And Equity Securities Accumulated Gross Unrealized Loss Before Tax
DebtAndEquitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2023Q1 rkda Debt And Equity Securities
DebtAndEquitySecurities
20501000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
0
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
1000
CY2023Q1 rkda Proceeds From Sale Of Equity Method Investments In Accounts And Other Receivable
ProceedsFromSaleOfEquityMethodInvestmentsInAccountsAndOtherReceivable
285000
CY2022Q1 rkda Proceeds From Sale Of Equity Method Investments In Accounts And Other Receivable
ProceedsFromSaleOfEquityMethodInvestmentsInAccountsAndOtherReceivable
0
CY2023Q1 rkda Entity Place Of Incorporation
EntityPlaceOfIncorporation
Arizona
CY2023Q1 rkda Entity Incorporation Year Of Incorporation
EntityIncorporationYearOfIncorporation
2002
CY2023Q1 rkda Entity Reincorporation State Country Name
EntityReincorporationStateCountryName
Delaware
CY2023Q1 rkda Entity Reincorporation Date Of Reincorporation
EntityReincorporationDateOfReincorporation
2015-03
CY2023Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
In February 2023, the Company’s board of directors approved a reverse split of 40:1 on the Company’s issued and outstanding common stock.
CY2023Q1 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
19092
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-122000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-267200000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23000000.0
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-9400000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3500000
CY2022 us-gaap Profit Loss
ProfitLoss
-15600000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14000000.0
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23000000.0
CY2022Q4 rkda Debt And Equity Securities Amortized Cost Basis
DebtAndEquitySecuritiesAmortizedCostBasis
18620000
CY2022Q4 rkda Debt And Equity Securities Accumulated Gross Unrealized Gain Before Tax
DebtAndEquitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q4 rkda Debt And Equity Securities Accumulated Gross Unrealized Loss Before Tax
DebtAndEquitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2022Q4 rkda Debt And Equity Securities
DebtAndEquitySecurities
18620000
CY2023Q1 us-gaap Inventory Write Down
InventoryWriteDown
23000
CY2022Q1 us-gaap Inventory Write Down
InventoryWriteDown
368000
CY2023Q1 rkda Inventory Raw Materials Current And Non Current
InventoryRawMaterialsCurrentAndNonCurrent
582000
CY2022Q4 rkda Inventory Raw Materials Current And Non Current
InventoryRawMaterialsCurrentAndNonCurrent
610000
CY2023Q1 rkda Inventory Goods In Process Current And Non Current
InventoryGoodsInProcessCurrentAndNonCurrent
114000
CY2022Q4 rkda Inventory Goods In Process Current And Non Current
InventoryGoodsInProcessCurrentAndNonCurrent
0
CY2023Q1 rkda Inventory Finished Goods Current And Non Current
InventoryFinishedGoodsCurrentAndNonCurrent
2655000
CY2022Q4 rkda Inventory Finished Goods Current And Non Current
InventoryFinishedGoodsCurrentAndNonCurrent
2728000
CY2023Q1 rkda Inventory Current And Non Current Net
InventoryCurrentAndNonCurrentNet
3351000
CY2022Q4 rkda Inventory Current And Non Current Net
InventoryCurrentAndNonCurrentNet
3338000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3466000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3515000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2844000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2811000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
622000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
704000
CY2023Q1 us-gaap Depreciation
Depreciation
71000
CY2022Q1 us-gaap Depreciation
Depreciation
149000
CY2023Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
19000
CY2022Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
328000
CY2023Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
30000
CY2022Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
787000
CY2023Q1 us-gaap Assets Held For Sale Long Lived Fair Value Disclosure
AssetsHeldForSaleLongLivedFairValueDisclosure
87000
CY2022Q4 us-gaap Assets Held For Sale Long Lived Fair Value Disclosure
AssetsHeldForSaleLongLivedFairValueDisclosure
87000
CY2023Q1 rkda Debt And Equity Securities Amortized Cost Basis
DebtAndEquitySecuritiesAmortizedCostBasis
20501000
CY2023Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
20501000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
18620000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2700
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.17
CY2023Q1 rkda Share Based Compensation Arrangement By Share Based Payment Award Grants Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsOutstandingIntrinsicValue
0
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
342570
CY2023Q1 rkda Stock Issued During Period Shares Related To Exercise Of Warrants
StockIssuedDuringPeriodSharesRelatedToExerciseOfWarrants
56813
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
769532
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-122000
CY2023Q1 rkda Operating Lease Term Expiration Month And Year
OperatingLeaseTermExpirationMonthAndYear
2024-05
CY2022Q2 rkda Payments For Termination Fees
PaymentsForTerminationFees
47000
CY2023Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
Some leases (the Dallas and Davis offices, a warehouse, and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years.
CY2023Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1618000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1848000
CY2023Q1 rkda Operating Lease Assets
OperatingLeaseAssets
1618000
CY2022Q4 rkda Operating Lease Assets
OperatingLeaseAssets
1848000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1014000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1010000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
760000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1007000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1774000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2017000
CY2023Q1 us-gaap Lease Cost
LeaseCost
86000
CY2022Q1 us-gaap Lease Cost
LeaseCost
192000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y2M12D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M24D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.064
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
CY2022 rkda Stock Issued During Period Shares Related To Exercise Of Warrants
StockIssuedDuringPeriodSharesRelatedToExerciseOfWarrants
0
CY2023Q1 rkda Number Of Equity Incentive Plans
NumberOfEquityIncentivePlans
2
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
60002
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
114.80
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
858
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
47.06
CY2023Q1 rkda Share Based Compensation Arrangement By Share Based Payment Award Forfeiture Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureOutstandingIntrinsicValue
39054000.00
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
CY2023Q1 rkda Share Based Compensation Arrangement By Share Based Payment Award Expired Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiredOutstandingIntrinsicValue
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
61844
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
110.91
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
56615
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
116.59
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
25725
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
194.30
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
988000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M12D
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
212000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
260000
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1820494
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
326490

Files In Submission

Name View Source Status
rkda-20230331_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0000950170-23-022199-index-headers.html Edgar Link pending
0000950170-23-022199-index.html Edgar Link pending
0000950170-23-022199.txt Edgar Link pending
0000950170-23-022199-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rkda-20230331.htm Edgar Link pending
rkda-20230331.xsd Edgar Link pending
rkda-ex31_1.htm Edgar Link pending
rkda-ex31_2.htm Edgar Link pending
rkda-ex32_1.htm Edgar Link pending
rkda-ex32_2.htm Edgar Link pending
Show.js Edgar Link pending
rkda-20230331_def.xml Edgar Link unprocessable
rkda-20230331_lab.xml Edgar Link unprocessable
rkda-20230331_pre.xml Edgar Link unprocessable
rkda-20230331_htm.xml Edgar Link completed